Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
  1. Home
  3. Research Domains

Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer.

Chaitanya R Acharya1, David S Hsu, Carey K Anders

  • 1Duke Institute for Genome Sciences and Policy, Duke University, Durham, North Carolina 27708, USA.

JAMA
|April 5, 2008

Related Experiment Videos

View abstract on PubMed

Summary

Related Concept Videos

  • Biomedical And Clinical Sciences
  • Oncology And Carcinogenesis
  • Predictive And Prognostic Markers
  • Gene Expression Signatures, Clinicopathological Features, And Individualized Therapy In Breast Cancer.
    • This summary is machine-generated.

    Integrating gene expression signatures with clinical data refines prognosis for early stage breast cancer patients. This genomic approach identifies distinct subphenotypes, improving risk stratification and guiding personalized therapeutic strategies.

    Area of Science:

    • Oncology
    • Genomics
    • Biostatistics

    Background:

    • Gene expression profiling offers potential for improved prognostic and therapeutic strategies in breast carcinoma.
    • Accurate prognosis and tailored therapies are crucial for early-stage breast cancer management.

    Purpose of the Study:

    • To integrate genomic information with clinical and pathological risk factors.
    • To refine prognosis and enhance therapeutic strategies for early-stage breast cancer.

    Main Methods:

    • Retrospective analysis of 964 early-stage breast cancer patients with microarray data.
    • Application of gene expression signatures and clinicopathological variables to assess relapse risk and chemotherapy sensitivity.
    • Identification of genomic subphenotypes and their correlation with relapse risk scores.

    Main Results:

    • Prognostically significant genomic clusters associated with oncogenic pathways and tumor microenvironment were identified within different risk groups.
    • These genomic clusters independently refined relapse-free survival predictions compared to clinicopathological models alone.
    • Genomic clusters demonstrated distinct sensitivity patterns to cytotoxic therapies, highlighting heterogeneity.

    Conclusions:

    • Incorporating gene expression signatures into clinical risk stratification shows promise for refining breast cancer prognosis.
    • Further prospective studies are necessary to validate the utility of this approach for individualizing treatment strategies.

    Related Experiment Videos